0001628280-25-036713
SEC filingStrong membership growth and margin improvement drove profitability, with revenue up 49% and net income turning positive in Q2 2025.
In the second quarter of 2025, Alignment Healthcare delivered strong financial results. Total revenue increased 49.0% to $1.015 billion, driven by 27.8% growth in Health Plan Membership to 223,700 members and higher per-member revenue from increased CMS benchmark rates and Part D benefits under the Inflation Reduction Act. Medical benefits ratio (MBR) improved 200 basis points year-over-year to 86.7%, reflecting favorable unit economics as the mix shifted toward returning members with better cost management. Operating income swung to a gain of $22.7 million from a loss of $18.4 million in the prior year quarter. Net income turned positive at $15.7 million, compared to a net loss of $24.0 million. Adjusted EBITDA increased tenfold to $45.9 million, demonstrating operational leverage.
The company operates as a single reportable segment—Medicare Advantage health plans. While no segment-level financials are broken out, the primary driver of performance is membership growth and the associated medical cost ratio. The MD&A highlights that new members typically have higher MBRs, but returning members show improving MBR trends over time, validating the company's clinical model. The company's market share in its operating areas remains modest at about 5%, providing ample room for continued expansion.
Management expects to continue investing in its AVA platform, new market expansions, and innovative product offerings to drive growth. The company anticipates moderate seasonality due to the Inflation Reduction Act's benefit redesign. No specific numeric guidance was provided. Liquidity remains strong with $503.8 million in cash and investments, which management believes is sufficient to fund operations and organic growth for at least the next 12 months. The company also noted its intention to discontinue the ACO REACH model by year-end 2025, focusing resources on core health plan operations.
The Notes reveal a strong liquidity position with $470.3M cash and equivalents (from the balance sheet, but referenced in Note 3 as part of fair value disclosures). Total assets grew to $1.0B, driven by a $129M increase in accounts receivable and a $165M rise in medical expenses payable. The latter reflects higher claims volume and timing. The company maintains $33.5M in short-term U.S. Treasury investments and $2.3M in restricted certificates of deposit. Long-term debt consists solely of $330M in 4.25% convertible senior notes due 2029, net of $7.7M issuance costs, resulting in a carrying value of $322.3M. No current maturities exist.
The Notes disclose no material purchase commitments for inventory or capacity. Legal contingencies include a tentative settlement of a class action wage-and-hour lawsuit for $0.9M (accrued) and a $0.95M settlement for stockholder litigation paid in April 2025. A RADV audit for payment year 2019 was initiated in June 2025; the company cannot estimate the potential adjustment. No other contractual obligations are discussed.
The company did not repurchase shares or pay dividends. Debt activity: no new borrowings in 2025; the convertible notes were issued in November 2024 to refinance the Oxford term loan. Capital expenditures are not explicitly detailed in the Notes, but the cash flow statement (outside Notes) shows $16.3M in property and equipment additions for the six months. Equity-based compensation totaled $32.7M, with $29.3M in SG&A.
The company operates as a single reportable segment: providing healthcare services to seniors through Medicare Advantage plans. The CODM reviews consolidated net income (loss) and significant expenses: medical expenses (less depreciation and equity comp), SG&A (less equity comp), and other segment items. Geographic mix is not disclosed at the note level, but operations are in California, North Carolina, Nevada, Arizona, and Texas. Premium revenue is earned from CMS and is subject to risk adjustment and minimum medical loss ratio (85%) requirements.
Net income for H1 2025 was $6.3M, but operating cash flow (CFO) reached $45.7M, a seven-fold multiple. This divergence is largely due to non-cash charges (depreciation, equity-based compensation) and substantial working capital inflows, particularly a $165.4M increase in medical expenses payable, which offset a $129.3M increase in accounts receivable.
Capital expenditures (capex) totaled $16.3M, resulting in a capex-to-CFO ratio of ~36%, indicating moderate investment intensity. Free cash flow, while not explicitly disclosed, would be CFO minus capex, or approximately $29.4M. No share repurchases or dividends were reported. Financing activities provided $1.8M, mainly from stock option exercises, with no new debt issuance.
Overall, cash generation improved significantly year-over-year, driven by operational leverage and favorable working capital dynamics. The company ended the period with $472.4M in cash and restricted cash, up from $341.1M at June 30, 2024.